Abstract:Background: Irinotecan and cisplatin individually are active in non-small cell lung carcinoma (NSCLC). Each is synergistic with radiation. Dosages of 65 mg/m2 of irinotecan and 30 mg/m2 of cisplatin Q weekly times four every 6 weeks yielded a 36% response rate and median survival of 11.6 months in advanced NSCLC (Jagasia et al.; Clinical Cancer Reserch 7: 68, 2001). A weekly schedule for each agent (versus less frequent doses) limits toxicity and increases the opportunity for radiosensitization. Materials and Methods: We initiated a phase I study of weekly irinotecan and cisplatin during radical thoracic radiation (TRT). Cisplatin was fixed at 25 mg/m2 Q weekly times seven. Irinotecan was dosed initially at 30 mg/m2 per week for 7 weeks and was increased by 10 mg/m2 per week in three- to six-patient cohorts. TRT was administered in 34 single daily fractions to 63 Gy. Eligibility stipulated locally advanced NSCLC; Eastern Cooperative Oncology Group performance status 0 to 1; ≤10% unintended weight loss; and adequate physiologic indices. Results: Fifteen patients were accrued: nine were stage IIIB, five were stage IIIA, and one had isolated mediastinal node recurrence after prior surgery. Median age was 65 years (range, 47–77). Seven patients received irinotecan at a dose of 30 mg/m2 per week; (dose level 1). Seven other patients received irinotecan at a dose of 40 mg/m2 per week; (dose level 2). The one other patient received irinotecan in doses of 50 mg/m2 per week; (dose level 3). Neutropenic fever occurred in one patient each at dose levels 1 and 2. Grade 4 neutropenia occurred in three patients at each dose level. Transient grade 3 diarrhea occurred in one patient at dose level 1. Esophagitis of grade 3 or higher occurred in one patient each at dose levels 2 and 3. There was one late grade 3 pneumonitis at dose level 2. Delivered irinotecan dose intensity for dose level 1 was 27 mg/m2 per week; for dose level 2, it was 31.4 mg/m2 per week. Nine of 13 evaluable patients (69%) responded. At median potential follow-up of 5 years, 14 have progressed, and 11 have died. Projected median survival is 28 months; one patient who was treated for mediastinal node recurrence remains free from progression at 6 years. Conclusion: Weekly irinotecan and cisplatin combined with radical TRT (63 Gy) is active and fairly well tolerated in locally advanced NSCLC. In combination with fixed-dose cisplatin (25 mg/m2 per week), the maximum-tolerated dose of irinotecan is 30 mg/m2 per week.

Cisplatin As a Radiosensitizer in Clinical Practice: a Pilot Study.

Clinical Pharmacokinetic Study of Cisplatin in Enhancing Cervical Cancer Radiosensitivity

Clinical Benefit of Gemcitabine Plus Cisplatin 3-Week Regimen for Patients with Advanced Non-Small Cell Lung Cancer: a Prospective Observational Study.

RRM1 and BRCA1 Mrna Expression Levels and Clinical Outcome of Advanced NSCLC Patients Treated with Cisplatin-Based Chemotherapy

Pharmacodynamics of Cisplatin in Patients with Nonsmall-cell Lung Cancer

In vitro and in vivo study of a nanoliposomal cisplatin as a radiosensitizer.

A phase I / II study of concurrent cisplatin chemotherapy in patients with carcinoma of the cervix receiving pelvic radiotherapy

A pilot study of protracted low dose cisplatin and etoposide with concurrent thoracic radiotherapy in unresectable stage III nonsmall cell lung cancer

A phase Ⅰ / Ⅱ study of concurrent cisplatin chemotherapy in patients with carcinoma of the cervix receiving pelvic radiotherapy

The Concentration Changes of Lobaplatin and Cisplatin Injected Intravenously in Mice Bearing Lewis Lung Carcinoma

Pemetrexed and Cisplatin Combination with Concurrent Whole Brain Radiotherapy in Patients with Brain Metastases of Lung Adenocarcinoma: a Single-Arm Phase II Clinical Trial

Phase I Study of Radical Thoracic Radiation, Weekly Irinotecan, and Cisplatin in Locally Advanced Non-small Cell Lung Carcinoma

Clinical Effects of Cisplatin Combined with Temozolomide and Radiotherapy in Treatment of Glioblastomas after Surgery

Superior Antitumor Efficiency of Cisplatin-Loaded Nanoparticles by Intratumoral Delivery with Decreased Tumor Metabolism Rate

[A Clinical Study on the Combination of Gemcitabine and Cisplatin in the Treatment of Advanced Non-Small Cell Lung Cancer].

Advances in Our Understanding of the Molecular Mechanisms of Action of Cisplatin in Cancer Therapy

Clinical Study of Treatment of Locally Advanced Non-Small Cell Lung Cancer by Intensity Modulated Irradiation Combined with Pemetrexed and Cisplatin

Full-dose Pemetrexed Plus Cisplatin Combined with Concurrent Thoracic Radiotherapy for Previously Untreated Advanced Nonsquamous Non-Small Cell Lung Cancer.

Cisplatin in cancer treatment

Cisplatin-Based Combination Therapy for Enhanced Cancer Treatment